New Autoimmune Disease Treatments Could Cause Fewer Side Effects
Because many of the current treatments for autoimmune diseases leave patients at greater risk of developing other opportunistic illnesses, a research team at the University of Oxford in England has been using genetics to possibly minimize the side effects of treatment.
Similar Efficacy with Use of Subcutaneous and Intravenous Immunoglobulin in CIDP and MMN: Meta-Analysis
Canadian investigators conducted a meta-analysis of published reports evaluating the efficacy and safety of subcutaneous and intravenous immunoglobulin therapy for two chronic autoimmune
neuropathies.
Human Alpha-1 Antitrypsin Improves Early Posttransplant Lung Function in Pig Lung Transplant Model
Investigators at Toronto General Research Institute used a pig lung transplant model to determine whether human A1AT could attenuate reperfusion injury after prolonged hypothermic preservation.
FDA Approves First Human Trial of a Zika Vaccine
The U.S. Food and Drug Administration has approved the first human trial of an experimental Zika virus vaccine.
Study Finds Influenza Vaccine’s Effectiveness Can Be Improved
Research conducted at the University of Texas at Austin found that how the influenza (flu) vaccine produces antibodies to protect against disease could be used to improve the vaccine.
Phase II Trial Launched of AAT for the Prevention of Lung Transplant Rejection
Kamada has initiated a Phase II clinicaltrial with its proprietary Alpha-1Antitrypsin (AAT) for the prevention oflung transplant rejection.
IDELVION Prevents Bleeds and Reduces Drug Consumption in Hemophilia B Patients
Results from the Phase III PROLONG9FP ongoing extension clinical development program evaluating the long-term efficacy and safety of IDELVION (coagulation factor IX [recombinant], albumin fusion protein) showed that extended prophylaxis treatment regimens effectively prevented bleeds while also reducing overall IDELVION consumption.
GSK’s Shingles Vaccine Effective in Adults 70-Plus Years Old
A randomized Phase III study (ZOE-70) of GlaxoSmithKline’s investigational shingles vaccine, Shingrix, showed 90 percent efficacy in adults aged 70 years and older that is maintained for at least four years.
Stem Cell Therapies: The Era of Regenerative Medicine?
Advancements in stem cell therapy may soon eliminate surgeries and cure disease, but first, the debate between two different schools of thought concerning how best to proceed needs to be resolved.
Recombinant Human Soluble Thrombomodulin May Improve Outcomes in Transplant-Associated Thrombotic Microangiopathy
Intravenous administration of recombinant soluble thrombomodulin (rTM) may improve recovery and survival compared to other treatments in patients with transplant-associated thrombotic microangiopathy (TA-TMA) after hematopoietic stem cell transplantation (HSCT), according to a retrospective analysis of 254 consecutive patients at a single Japanese institution.
